COVID-19 Vaccine Addressable Market Is Set To Reach 41.6 USD billion By 2033, Growing At A CAGR Of 21.2
COVID-19 Vaccine Addressable Market by By Vaccine Type: (mRNA vaccines, DNA vaccines, Vector vaccines, Protein subunit vaccines, Inactivated vaccines, Whole virion vaccines ), by By Application: (Prophylaxis, Treatment ), by By End User: (Healthcare professionals, General public), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2025-2033
Key Insights
The COVID-19 Vaccine Addressable Market size was valued at USD 41.6 USD billion in 2023 and is projected to reach USD 159.81 USD billion by 2032, exhibiting a CAGR of 21.2 % during the forecast period. COVID-19 vaccine addressable refers to the ability to identify, reach, and target specific populations or groups that are eligible or in need of COVID-19 vaccination. This term is often used in discussions related to the distribution and administration of vaccines, especially as it pertains to ensuring equitable access across different regions, age groups, and demographics. The concept of "addressable" typically includes the identification of individuals or populations who may benefit from vaccination
COVID-19 Vaccine Addressable Trends
- Growing demand for vaccines due to the increase in COVID-19 cases
- Increase in government funding for vaccine research and development
- Development of new and improved vaccines
- Collaborations between pharmaceutical companies and research institutions
- Expansion of vaccine manufacturing capacity
Driving Forces: What's Propelling the COVID-19 Vaccine Addressable Market
- Increasing prevalence of COVID-19 cases: The COVID-19 pandemic has resulted in a significant increase in the number of cases worldwide. This has led to a growing demand for vaccines to prevent the spread of the virus.
- Government initiatives to procure and distribute vaccines: Governments around the world have launched initiatives to procure and distribute vaccines to their populations. This has provided a major boost to the market for COVID-19 vaccines.
- Development of new and improved vaccines: Pharmaceutical companies are continuously developing new and improved vaccines to combat COVID-19. These vaccines are more effective and have fewer side effects, which is driving demand for them.
- Collaborations between pharmaceutical companies and research institutions: Pharmaceutical companies are collaborating with research institutions to develop and test new vaccines. This collaboration is helping to accelerate the development of vaccines.
- Expansion of vaccine manufacturing capacity: Vaccine manufacturers are expanding their production capacity to meet the growing demand for vaccines. This is ensuring that there is enough supply of vaccines to meet the needs of the population.
Challenges and Restraints in COVID-19 Vaccine Addressable Market
- Vaccine hesitancy: Some people are hesitant to get vaccinated against COVID-19 due to concerns about safety and efficacy. This hesitancy is a major challenge to the market for COVID-19 vaccines.
- Supply chain disruptions: The COVID-19 pandemic has disrupted global supply chains, which has made it difficult to procure raw materials and components for vaccine manufacturing. This has led to delays in vaccine production and delivery.
- Cost of vaccines: The cost of COVID-19 vaccines is a major concern for many people. This is especially true in developing countries, where people have limited access to healthcare.
- Long-term efficacy of vaccines: The long-term efficacy of COVID-19 vaccines is still unknown. This is a concern for some people, who may be hesitant to get vaccinated until more data is available.
- Emergence of new variants: The emergence of new variants of COVID-19 is a concern for vaccine manufacturers. These variants may be more resistant to vaccines, which could reduce their efficacy.
Emerging Trends in COVID-19 Vaccine Addressable
- Development of mRNA vaccines: mRNA vaccines are a new type of vaccine that has been shown to be highly effective against COVID-19. These vaccines are easy to manufacture and can be quickly adapted to new variants of the virus.
- Use of artificial intelligence (AI): AI is being used to develop and test new vaccines. This is helping to accelerate the development process and identify potential candidates.
- Personalized vaccines: Personalized vaccines are being developed to target specific individuals. These vaccines are more effective and have fewer side effects.
- Combination vaccines: Combination vaccines are being developed to protect against multiple strains of COVID-19. This is helping to reduce the need for multiple vaccinations.
- Global vaccine distribution: Global vaccine distribution is a major challenge. Pharmaceutical companies and governments are working together to ensure that vaccines are distributed equitably around the world.
Growth Catalysts in COVID-19 Vaccine Addressable Industry
- Government support: Governments around the world are providing financial support to vaccine manufacturers. This is helping to accelerate the development and production of vaccines.
- Public-private partnerships: Public-private partnerships are being formed to develop and distribute vaccines. These partnerships are bringing together the resources of government agencies, pharmaceutical companies, and non-profit organizations.
- Technological advancements: Technological advancements are helping to accelerate the development and production of vaccines. These advancements include the use of mRNA vaccines and AI.
- Increasing demand for vaccines: The growing demand for vaccines is a major growth catalyst for the market. This demand is being driven by the increasing prevalence of COVID-19 cases and the desire to protect people from the virus.
Market Segmentation: COVID-19 Vaccine Addressable Analysis
By Vaccine Type:
- mRNA vaccines
- DNA vaccines
- Vector vaccines
- Protein subunit vaccines
- Inactivated vaccines
- Whole virion vaccines
By Application:
- Prophylaxis
- Treatment
By End User:
- Healthcare professionals
- General public
Leading Players in the COVID-19 Vaccine Addressable Market
Significant developments in COVID-19 Vaccine Addressable Sector
- In December 2020, Pfizer and BioNTech announced that their COVID-19 vaccine was 95% effective in preventing symptomatic COVID-19.
- In January 2021, Moderna announced that its COVID-19 vaccine was 94% effective in preventing symptomatic COVID-19.
- In February 2021, Johnson & Johnson announced that its COVID-19 vaccine was 66% effective in preventing symptomatic COVID-19.
- In March 2021, AstraZeneca and Oxford University announced that their COVID-19 vaccine was 70% effective in preventing symptomatic COVID-19.
- In April 2021, Novavax announced that its COVID-19 vaccine was 90% effective in preventing symptomatic COVID-19.
Comprehensive Coverage COVID-19 Vaccine Addressable Market Report
The report provides comprehensive coverage of the following:
- Market size and growth forecasts
- Key market trends and drivers
- Challenges and restraints
- Market segmentation
- Competitive landscape
- Company profiles
- Recent developments
- Future outlook
Regional Insight
The COVID-19 vaccine addressable market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is the largest market for COVID-19 vaccines, followed by Europe. Asia-Pacific is expected to be the fastest-growing market for COVID-19 vaccines during the forecast period.
Pricing Analysis
The price of COVID-19 vaccines varies depending on the type of vaccine, the manufacturer, and the country where it is purchased. In the United States, the Pfizer-BioNTech vaccine costs $19.50 per dose, the Moderna vaccine costs $15.25 per dose, and the Johnson & Johnson vaccine costs $10 per dose.
Import And Export Analysis
The import and export of COVID-19 vaccines is a major concern for governments around the world. Some countries have banned the export of vaccines, while others have imposed tariffs on imported vaccines. This is making it difficult for countries to access the vaccines they need to protect their populations.
Segmentation
The COVID-19 vaccine addressable market is segmented into the following categories:
- By Vaccine Type: mRNA vaccines, DNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, whole virion vaccines
- By Application: Prophylaxis, treatment
- By End User: Healthcare professionals, general public
Patent/Trademark Analysis
There are a number of patents and trademarks associated with COVID-19 vaccines. These patents and trademarks protect the intellectual property of the companies that developed the vaccines.
COVID-19 Vaccine Addressable Market REPORT HIGHLIGHTS
Aspects | Details |
---|---|
Study Period | 2019-2033 |
Base Year | 2024 |
Estimated Year | 2025 |
Forecast Period | 2025-2033 |
Historical Period | 2019-2024 |
Growth Rate | CAGR of 21.2% from 2019-2033 |
Segmentation |
|
Frequently Asked Questions
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Public Awareness for Safer Medicines to Stimulate Market Value
- 3.3. Market Restrains
- 3.3.1. Lack of Diagnosis and Treatment in Developing Countries to Limit the Demand for Wound Dressings
- 3.4. Market Trends
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global COVID-19 Vaccine Addressable Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 5.1.1. mRNA vaccines
- 5.1.2. DNA vaccines
- 5.1.3. Vector vaccines
- 5.1.4. Protein subunit vaccines
- 5.1.5. Inactivated vaccines
- 5.1.6. Whole virion vaccines
- 5.2. Market Analysis, Insights and Forecast - by By Application:
- 5.2.1. Prophylaxis
- 5.2.2. Treatment
- 5.3. Market Analysis, Insights and Forecast - by By End User:
- 5.3.1. Healthcare professionals
- 5.3.2. General public
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. North America
- 5.4.2. South America
- 5.4.3. Europe
- 5.4.4. Middle East & Africa
- 5.4.5. Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 6. North America COVID-19 Vaccine Addressable Market Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 6.1.1. mRNA vaccines
- 6.1.2. DNA vaccines
- 6.1.3. Vector vaccines
- 6.1.4. Protein subunit vaccines
- 6.1.5. Inactivated vaccines
- 6.1.6. Whole virion vaccines
- 6.2. Market Analysis, Insights and Forecast - by By Application:
- 6.2.1. Prophylaxis
- 6.2.2. Treatment
- 6.3. Market Analysis, Insights and Forecast - by By End User:
- 6.3.1. Healthcare professionals
- 6.3.2. General public
- 6.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 7. South America COVID-19 Vaccine Addressable Market Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 7.1.1. mRNA vaccines
- 7.1.2. DNA vaccines
- 7.1.3. Vector vaccines
- 7.1.4. Protein subunit vaccines
- 7.1.5. Inactivated vaccines
- 7.1.6. Whole virion vaccines
- 7.2. Market Analysis, Insights and Forecast - by By Application:
- 7.2.1. Prophylaxis
- 7.2.2. Treatment
- 7.3. Market Analysis, Insights and Forecast - by By End User:
- 7.3.1. Healthcare professionals
- 7.3.2. General public
- 7.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 8. Europe COVID-19 Vaccine Addressable Market Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 8.1.1. mRNA vaccines
- 8.1.2. DNA vaccines
- 8.1.3. Vector vaccines
- 8.1.4. Protein subunit vaccines
- 8.1.5. Inactivated vaccines
- 8.1.6. Whole virion vaccines
- 8.2. Market Analysis, Insights and Forecast - by By Application:
- 8.2.1. Prophylaxis
- 8.2.2. Treatment
- 8.3. Market Analysis, Insights and Forecast - by By End User:
- 8.3.1. Healthcare professionals
- 8.3.2. General public
- 8.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 9. Middle East & Africa COVID-19 Vaccine Addressable Market Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 9.1.1. mRNA vaccines
- 9.1.2. DNA vaccines
- 9.1.3. Vector vaccines
- 9.1.4. Protein subunit vaccines
- 9.1.5. Inactivated vaccines
- 9.1.6. Whole virion vaccines
- 9.2. Market Analysis, Insights and Forecast - by By Application:
- 9.2.1. Prophylaxis
- 9.2.2. Treatment
- 9.3. Market Analysis, Insights and Forecast - by By End User:
- 9.3.1. Healthcare professionals
- 9.3.2. General public
- 9.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 10. Asia Pacific COVID-19 Vaccine Addressable Market Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 10.1.1. mRNA vaccines
- 10.1.2. DNA vaccines
- 10.1.3. Vector vaccines
- 10.1.4. Protein subunit vaccines
- 10.1.5. Inactivated vaccines
- 10.1.6. Whole virion vaccines
- 10.2. Market Analysis, Insights and Forecast - by By Application:
- 10.2.1. Prophylaxis
- 10.2.2. Treatment
- 10.3. Market Analysis, Insights and Forecast - by By End User:
- 10.3.1. Healthcare professionals
- 10.3.2. General public
- 10.1. Market Analysis, Insights and Forecast - by By Vaccine Type:
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2024
- 11.2. Company Profiles
- 11.2.1 GlaxoSmithKline
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Pfizer
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Merck
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Sanofi
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.1 GlaxoSmithKline
- Figure 1: Global COVID-19 Vaccine Addressable Market Revenue Breakdown (USD billion, %) by Region 2024 & 2032
- Figure 2: Global COVID-19 Vaccine Addressable Market Volume Breakdown (million units, %) by Region 2024 & 2032
- Figure 3: Global COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Vaccine Type: 2024 & 2032
- Figure 4: Global COVID-19 Vaccine Addressable Market Volume (million units), by By Vaccine Type: 2024 & 2032
- Figure 5: Global COVID-19 Vaccine Addressable Market Revenue Share (%), by By Vaccine Type: 2024 & 2032
- Figure 6: Global COVID-19 Vaccine Addressable Market Volume Share (%), by By Vaccine Type: 2024 & 2032
- Figure 7: Global COVID-19 Vaccine Addressable Market Forecast (USD billion), by mRNA vaccines 2021 & 2032
- Figure 8: Global COVID-19 Vaccine Addressable Market Forecast (million units), by mRNA vaccines 2021 & 2032
- Figure 9: Global COVID-19 Vaccine Addressable Market Forecast (USD billion), by DNA vaccines 2021 & 2032
- Figure 10: Global COVID-19 Vaccine Addressable Market Forecast (million units), by DNA vaccines 2021 & 2032
- Figure 11: Global COVID-19 Vaccine Addressable Market Forecast (USD billion), by Vector vaccines 2021 & 2032
- Figure 12: Global COVID-19 Vaccine Addressable Market Forecast (million units), by Vector vaccines 2021 & 2032
- Figure 13: Global COVID-19 Vaccine Addressable Market Forecast (USD billion), by Protein subunit vaccines 2021 & 2032
- Figure 14: Global COVID-19 Vaccine Addressable Market Forecast (million units), by Protein subunit vaccines 2021 & 2032
- Figure 15: Global COVID-19 Vaccine Addressable Market Forecast (USD billion), by Inactivated vaccines 2021 & 2032
- Figure 16: Global COVID-19 Vaccine Addressable Market Forecast (million units), by Inactivated vaccines 2021 & 2032
- Figure 17: Global COVID-19 Vaccine Addressable Market Forecast (USD billion), by Whole virion vaccines 2021 & 2032
- Figure 18: Global COVID-19 Vaccine Addressable Market Forecast (million units), by Whole virion vaccines 2021 & 2032
- Figure 19: Global COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Application: 2024 & 2032
- Figure 20: Global COVID-19 Vaccine Addressable Market Volume (million units), by By Application: 2024 & 2032
- Figure 21: Global COVID-19 Vaccine Addressable Market Revenue Share (%), by By Application: 2024 & 2032
- Figure 22: Global COVID-19 Vaccine Addressable Market Volume Share (%), by By Application: 2024 & 2032
- Figure 23: Global COVID-19 Vaccine Addressable Market Forecast (USD billion), by Prophylaxis 2021 & 2032
- Figure 24: Global COVID-19 Vaccine Addressable Market Forecast (million units), by Prophylaxis 2021 & 2032
- Figure 25: Global COVID-19 Vaccine Addressable Market Forecast (USD billion), by Treatment 2021 & 2032
- Figure 26: Global COVID-19 Vaccine Addressable Market Forecast (million units), by Treatment 2021 & 2032
- Figure 27: Global COVID-19 Vaccine Addressable Market Revenue (USD billion), by By End User: 2024 & 2032
- Figure 28: Global COVID-19 Vaccine Addressable Market Volume (million units), by By End User: 2024 & 2032
- Figure 29: Global COVID-19 Vaccine Addressable Market Revenue Share (%), by By End User: 2024 & 2032
- Figure 30: Global COVID-19 Vaccine Addressable Market Volume Share (%), by By End User: 2024 & 2032
- Figure 31: Global COVID-19 Vaccine Addressable Market Forecast (USD billion), by Healthcare professionals 2021 & 2032
- Figure 32: Global COVID-19 Vaccine Addressable Market Forecast (million units), by Healthcare professionals 2021 & 2032
- Figure 33: Global COVID-19 Vaccine Addressable Market Forecast (USD billion), by General public 2021 & 2032
- Figure 34: Global COVID-19 Vaccine Addressable Market Forecast (million units), by General public 2021 & 2032
- Figure 35: Global COVID-19 Vaccine Addressable Market Revenue (USD billion), by Region 2024 & 2032
- Figure 36: Global COVID-19 Vaccine Addressable Market Volume (million units), by Region 2024 & 2032
- Figure 37: Global COVID-19 Vaccine Addressable Market Revenue Share (%), by Region 2024 & 2032
- Figure 38: Global COVID-19 Vaccine Addressable Market Volume Share (%), by Region 2024 & 2032
- Figure 39: North America COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Vaccine Type: 2024 & 2032
- Figure 40: North America COVID-19 Vaccine Addressable Market Volume (million units), by By Vaccine Type: 2024 & 2032
- Figure 41: North America COVID-19 Vaccine Addressable Market Revenue Share (%), by By Vaccine Type: 2024 & 2032
- Figure 42: North America COVID-19 Vaccine Addressable Market Volume Share (%), by By Vaccine Type: 2024 & 2032
- Figure 43: North America COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Application: 2024 & 2032
- Figure 44: North America COVID-19 Vaccine Addressable Market Volume (million units), by By Application: 2024 & 2032
- Figure 45: North America COVID-19 Vaccine Addressable Market Revenue Share (%), by By Application: 2024 & 2032
- Figure 46: North America COVID-19 Vaccine Addressable Market Volume Share (%), by By Application: 2024 & 2032
- Figure 47: North America COVID-19 Vaccine Addressable Market Revenue (USD billion), by By End User: 2024 & 2032
- Figure 48: North America COVID-19 Vaccine Addressable Market Volume (million units), by By End User: 2024 & 2032
- Figure 49: North America COVID-19 Vaccine Addressable Market Revenue Share (%), by By End User: 2024 & 2032
- Figure 50: North America COVID-19 Vaccine Addressable Market Volume Share (%), by By End User: 2024 & 2032
- Figure 51: North America COVID-19 Vaccine Addressable Market Revenue (USD billion), by Country 2024 & 2032
- Figure 52: North America COVID-19 Vaccine Addressable Market Volume (million units), by Country 2024 & 2032
- Figure 53: North America COVID-19 Vaccine Addressable Market Revenue Share (%), by Country 2024 & 2032
- Figure 54: North America COVID-19 Vaccine Addressable Market Volume Share (%), by Country 2024 & 2032
- Figure 55: South America COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Vaccine Type: 2024 & 2032
- Figure 56: South America COVID-19 Vaccine Addressable Market Volume (million units), by By Vaccine Type: 2024 & 2032
- Figure 57: South America COVID-19 Vaccine Addressable Market Revenue Share (%), by By Vaccine Type: 2024 & 2032
- Figure 58: South America COVID-19 Vaccine Addressable Market Volume Share (%), by By Vaccine Type: 2024 & 2032
- Figure 59: South America COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Application: 2024 & 2032
- Figure 60: South America COVID-19 Vaccine Addressable Market Volume (million units), by By Application: 2024 & 2032
- Figure 61: South America COVID-19 Vaccine Addressable Market Revenue Share (%), by By Application: 2024 & 2032
- Figure 62: South America COVID-19 Vaccine Addressable Market Volume Share (%), by By Application: 2024 & 2032
- Figure 63: South America COVID-19 Vaccine Addressable Market Revenue (USD billion), by By End User: 2024 & 2032
- Figure 64: South America COVID-19 Vaccine Addressable Market Volume (million units), by By End User: 2024 & 2032
- Figure 65: South America COVID-19 Vaccine Addressable Market Revenue Share (%), by By End User: 2024 & 2032
- Figure 66: South America COVID-19 Vaccine Addressable Market Volume Share (%), by By End User: 2024 & 2032
- Figure 67: South America COVID-19 Vaccine Addressable Market Revenue (USD billion), by Country 2024 & 2032
- Figure 68: South America COVID-19 Vaccine Addressable Market Volume (million units), by Country 2024 & 2032
- Figure 69: South America COVID-19 Vaccine Addressable Market Revenue Share (%), by Country 2024 & 2032
- Figure 70: South America COVID-19 Vaccine Addressable Market Volume Share (%), by Country 2024 & 2032
- Figure 71: Europe COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Vaccine Type: 2024 & 2032
- Figure 72: Europe COVID-19 Vaccine Addressable Market Volume (million units), by By Vaccine Type: 2024 & 2032
- Figure 73: Europe COVID-19 Vaccine Addressable Market Revenue Share (%), by By Vaccine Type: 2024 & 2032
- Figure 74: Europe COVID-19 Vaccine Addressable Market Volume Share (%), by By Vaccine Type: 2024 & 2032
- Figure 75: Europe COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Application: 2024 & 2032
- Figure 76: Europe COVID-19 Vaccine Addressable Market Volume (million units), by By Application: 2024 & 2032
- Figure 77: Europe COVID-19 Vaccine Addressable Market Revenue Share (%), by By Application: 2024 & 2032
- Figure 78: Europe COVID-19 Vaccine Addressable Market Volume Share (%), by By Application: 2024 & 2032
- Figure 79: Europe COVID-19 Vaccine Addressable Market Revenue (USD billion), by By End User: 2024 & 2032
- Figure 80: Europe COVID-19 Vaccine Addressable Market Volume (million units), by By End User: 2024 & 2032
- Figure 81: Europe COVID-19 Vaccine Addressable Market Revenue Share (%), by By End User: 2024 & 2032
- Figure 82: Europe COVID-19 Vaccine Addressable Market Volume Share (%), by By End User: 2024 & 2032
- Figure 83: Europe COVID-19 Vaccine Addressable Market Revenue (USD billion), by Country 2024 & 2032
- Figure 84: Europe COVID-19 Vaccine Addressable Market Volume (million units), by Country 2024 & 2032
- Figure 85: Europe COVID-19 Vaccine Addressable Market Revenue Share (%), by Country 2024 & 2032
- Figure 86: Europe COVID-19 Vaccine Addressable Market Volume Share (%), by Country 2024 & 2032
- Figure 87: Middle East & Africa COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Vaccine Type: 2024 & 2032
- Figure 88: Middle East & Africa COVID-19 Vaccine Addressable Market Volume (million units), by By Vaccine Type: 2024 & 2032
- Figure 89: Middle East & Africa COVID-19 Vaccine Addressable Market Revenue Share (%), by By Vaccine Type: 2024 & 2032
- Figure 90: Middle East & Africa COVID-19 Vaccine Addressable Market Volume Share (%), by By Vaccine Type: 2024 & 2032
- Figure 91: Middle East & Africa COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Application: 2024 & 2032
- Figure 92: Middle East & Africa COVID-19 Vaccine Addressable Market Volume (million units), by By Application: 2024 & 2032
- Figure 93: Middle East & Africa COVID-19 Vaccine Addressable Market Revenue Share (%), by By Application: 2024 & 2032
- Figure 94: Middle East & Africa COVID-19 Vaccine Addressable Market Volume Share (%), by By Application: 2024 & 2032
- Figure 95: Middle East & Africa COVID-19 Vaccine Addressable Market Revenue (USD billion), by By End User: 2024 & 2032
- Figure 96: Middle East & Africa COVID-19 Vaccine Addressable Market Volume (million units), by By End User: 2024 & 2032
- Figure 97: Middle East & Africa COVID-19 Vaccine Addressable Market Revenue Share (%), by By End User: 2024 & 2032
- Figure 98: Middle East & Africa COVID-19 Vaccine Addressable Market Volume Share (%), by By End User: 2024 & 2032
- Figure 99: Middle East & Africa COVID-19 Vaccine Addressable Market Revenue (USD billion), by Country 2024 & 2032
- Figure 100: Middle East & Africa COVID-19 Vaccine Addressable Market Volume (million units), by Country 2024 & 2032
- Figure 101: Middle East & Africa COVID-19 Vaccine Addressable Market Revenue Share (%), by Country 2024 & 2032
- Figure 102: Middle East & Africa COVID-19 Vaccine Addressable Market Volume Share (%), by Country 2024 & 2032
- Figure 103: Asia Pacific COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Vaccine Type: 2024 & 2032
- Figure 104: Asia Pacific COVID-19 Vaccine Addressable Market Volume (million units), by By Vaccine Type: 2024 & 2032
- Figure 105: Asia Pacific COVID-19 Vaccine Addressable Market Revenue Share (%), by By Vaccine Type: 2024 & 2032
- Figure 106: Asia Pacific COVID-19 Vaccine Addressable Market Volume Share (%), by By Vaccine Type: 2024 & 2032
- Figure 107: Asia Pacific COVID-19 Vaccine Addressable Market Revenue (USD billion), by By Application: 2024 & 2032
- Figure 108: Asia Pacific COVID-19 Vaccine Addressable Market Volume (million units), by By Application: 2024 & 2032
- Figure 109: Asia Pacific COVID-19 Vaccine Addressable Market Revenue Share (%), by By Application: 2024 & 2032
- Figure 110: Asia Pacific COVID-19 Vaccine Addressable Market Volume Share (%), by By Application: 2024 & 2032
- Figure 111: Asia Pacific COVID-19 Vaccine Addressable Market Revenue (USD billion), by By End User: 2024 & 2032
- Figure 112: Asia Pacific COVID-19 Vaccine Addressable Market Volume (million units), by By End User: 2024 & 2032
- Figure 113: Asia Pacific COVID-19 Vaccine Addressable Market Revenue Share (%), by By End User: 2024 & 2032
- Figure 114: Asia Pacific COVID-19 Vaccine Addressable Market Volume Share (%), by By End User: 2024 & 2032
- Figure 115: Asia Pacific COVID-19 Vaccine Addressable Market Revenue (USD billion), by Country 2024 & 2032
- Figure 116: Asia Pacific COVID-19 Vaccine Addressable Market Volume (million units), by Country 2024 & 2032
- Figure 117: Asia Pacific COVID-19 Vaccine Addressable Market Revenue Share (%), by Country 2024 & 2032
- Figure 118: Asia Pacific COVID-19 Vaccine Addressable Market Volume Share (%), by Country 2024 & 2032
- Table 1: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by Region 2019 & 2032
- Table 2: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by Region 2019 & 2032
- Table 3: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Vaccine Type: 2019 & 2032
- Table 4: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Vaccine Type: 2019 & 2032
- Table 5: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Application: 2019 & 2032
- Table 6: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Application: 2019 & 2032
- Table 7: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By End User: 2019 & 2032
- Table 8: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By End User: 2019 & 2032
- Table 9: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by Region 2019 & 2032
- Table 10: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by Region 2019 & 2032
- Table 11: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Vaccine Type: 2019 & 2032
- Table 12: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Vaccine Type: 2019 & 2032
- Table 13: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Application: 2019 & 2032
- Table 14: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Application: 2019 & 2032
- Table 15: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By End User: 2019 & 2032
- Table 16: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By End User: 2019 & 2032
- Table 17: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by Country 2019 & 2032
- Table 18: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by Country 2019 & 2032
- Table 19: United States COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 20: United States COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 21: Canada COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 22: Canada COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 23: Mexico COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 24: Mexico COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 25: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Vaccine Type: 2019 & 2032
- Table 26: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Vaccine Type: 2019 & 2032
- Table 27: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Application: 2019 & 2032
- Table 28: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Application: 2019 & 2032
- Table 29: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By End User: 2019 & 2032
- Table 30: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By End User: 2019 & 2032
- Table 31: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by Country 2019 & 2032
- Table 32: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by Country 2019 & 2032
- Table 33: Brazil COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 34: Brazil COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 35: Argentina COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 36: Argentina COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 37: Rest of South America COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 38: Rest of South America COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 39: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Vaccine Type: 2019 & 2032
- Table 40: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Vaccine Type: 2019 & 2032
- Table 41: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Application: 2019 & 2032
- Table 42: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Application: 2019 & 2032
- Table 43: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By End User: 2019 & 2032
- Table 44: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By End User: 2019 & 2032
- Table 45: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by Country 2019 & 2032
- Table 46: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by Country 2019 & 2032
- Table 47: United Kingdom COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 48: United Kingdom COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 49: Germany COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 50: Germany COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 51: France COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 52: France COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 53: Italy COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 54: Italy COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 55: Spain COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 56: Spain COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 57: Russia COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 58: Russia COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 59: Benelux COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 60: Benelux COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 61: Nordics COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 62: Nordics COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 63: Rest of Europe COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 64: Rest of Europe COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 65: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Vaccine Type: 2019 & 2032
- Table 66: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Vaccine Type: 2019 & 2032
- Table 67: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Application: 2019 & 2032
- Table 68: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Application: 2019 & 2032
- Table 69: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By End User: 2019 & 2032
- Table 70: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By End User: 2019 & 2032
- Table 71: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by Country 2019 & 2032
- Table 72: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by Country 2019 & 2032
- Table 73: Turkey COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 74: Turkey COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 75: Israel COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 76: Israel COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 77: GCC COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 78: GCC COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 79: North Africa COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 80: North Africa COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 81: South Africa COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 82: South Africa COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 83: Rest of Middle East & Africa COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 84: Rest of Middle East & Africa COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 85: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Vaccine Type: 2019 & 2032
- Table 86: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Vaccine Type: 2019 & 2032
- Table 87: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By Application: 2019 & 2032
- Table 88: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By Application: 2019 & 2032
- Table 89: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by By End User: 2019 & 2032
- Table 90: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by By End User: 2019 & 2032
- Table 91: Global COVID-19 Vaccine Addressable Market Revenue USD billion Forecast, by Country 2019 & 2032
- Table 92: Global COVID-19 Vaccine Addressable Market Volume million units Forecast, by Country 2019 & 2032
- Table 93: China COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 94: China COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 95: India COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 96: India COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 97: Japan COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 98: Japan COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 99: South Korea COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 100: South Korea COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 101: ASEAN COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 102: ASEAN COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 103: Oceania COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 104: Oceania COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 105: Rest of Asia Pacific COVID-19 Vaccine Addressable Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 106: Rest of Asia Pacific COVID-19 Vaccine Addressable Market Volume (million units) Forecast, by Application 2019 & 2032
Aspects | Details |
---|---|
Study Period | 2019-2033 |
Base Year | 2024 |
Estimated Year | 2025 |
Forecast Period | 2025-2033 |
Historical Period | 2019-2024 |
Growth Rate | CAGR of 21.2% from 2019-2033 |
Segmentation |
|
STEP 1 - Identification of Relevant Samples Size from Population Database
STEP 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note* : In applicable scenarios
STEP 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
STEP 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Related Reports
About Market Research Forecast
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.